Table 1.

Association between HPV16 status and HPV52 detection based on retesting of selected cervical/anal specimens using HPV52 type-specific PCRa

HPV52+ specimens/total specimens, NOR (95% CI) HPV16+ vs. HPV16 (reference)
StudyYears (recruitment and follow-up)/study populationHPV16+HPV16 (HPV+, α-9 type)HPV16 (HPV+, not α-9 type)CrudeAdjustedb
Ludwig–McGill1993–05; low-income females, 18–60 y, São Paulo, Brazil0/982/501/49N/EN/E
McGill–Concordia1996–02; female students, 17–45 y, Montreal, Canada2/1002/500/500.99 (0.14–7.17)0.97 (0.13–7.11)
HITCHc2005–13; female students with a male partner, 18–25 y, Montreal, Canada3/1000/500/50N/EN/E
BCCR2001–09; females with/without precancerous cervical lesions, 18–75 y, Montreal, Canada6/1002/501/492.04 (0.50–8.40)2.14 (0.47–9.57)
CCCaST2002–06; females screened for cervical cancer, 30–69 y, Montreal/St. John's, Canada4/1002/505/500.55 (0.16–1.95)0.43 (0.11–1.71)
HIPVIRGd2002–08; MSMs with HIV, 21–67 y, Montreal, Canada15/1003/501/504.24 (1.35–13.25)3.82 (1.19–12.26)
All studiese30/59811/3008/2981.62 (0.90–2.92)1.47 (0.76–2.82)
All studiese (HIPVIRG excluded)15/4988/2507/2481.00 (0.48–2.07)0.82 (0.35–1.93)

NOTE: Test for heterogeneity between studies: P = 0.08.

Abbreviations: MSM, men who have sex with men; N/E, not able to estimate.

  • aAll specimens were originally HPV52 negative in the source studies according to consensus primer PCR HPV DNA testing.

  • bAdjusted for age, lifetime number of sexual partners, and study (pooled analysis), except for CCCaST study (adjusted for age only).

  • cHITCH was the only study that included cervicovaginal specimens, and self- rather than provider-collected specimens.

  • dHIPVIRG was the only study that included anal specimens; all others included either cervicovaginal or cervical specimens.

  • eSome specimens from CCCaST study (n = 76) were excluded from adjusted pooled analysis because number of sexual partners information was not collected from certain subjects (St. John's study site only).